Admission inflammatory and immuno-nutritional indices and in-hospital mortality in emergency department patients admitted to intensive care: a retrospective cohort study - Scorecard - MDSpire
Advertisement
Association of Admission-Based Inflammatory and Nutritional Indices with In-Hospital Mortality in ICU Patients from the Emergency Department: A Retrospective Cohort Analysis
Clinical Scorecard: Association of Admission-Based Inflammatory and Nutritional Indices with In-Hospital Mortality in ICU Patients from the Emergency Department: A Retrospective Cohort Analysis
At a Glance
Category
Detail
Condition
In-hospital mortality in ICU patients
Key Mechanisms
Admission-based inflammatory indices and C-reactive protein-to-albumin ratio (CAR)
Target Population
Adult patients admitted to ICU from the emergency department
Care Setting
Emergency department to intensive care unit
Key Highlights
Higher median MII values and CAR levels in non-survivors compared to survivors (p < 0.001)
CAR showed the most consistent association with mortality
Discriminative performance of CAR was modest (AUC: 0.627)
MII variants had limited discriminatory performance (AUC range: 0.579–0.595)
Indices serve as adjunctive markers of inflammatory burden
Guideline-Based Recommendations
Diagnosis
Evaluate admission-based inflammatory indices for risk stratification
Management
Consider CAR and MII variants as adjunctive tools in clinical decision-making
Monitoring & Follow-up
Monitor inflammatory indices for changes in patient status
Risks
Increased risk of in-hospital mortality associated with higher inflammatory indices
Patient & Prescribing Data
Adult patients admitted to ICU from emergency department
Use of inflammatory indices may assist in early identification of high-risk patients
Clinical Best Practices
Incorporate CAR and MII indices in the assessment of critically ill patients
Utilize composite indices for a comprehensive view of inflammatory and nutritional status
Biomarker-guided patient selection may help identify patients with sepsis who could benefit from endotoxin-targeted therapy, although confirmatory evidence is still needed.
